Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS – Get Free Report) saw a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 29,440 shares, a decrease of 34.2% from the June 30th total of 44,712 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 59,063 shares, the days-to-cover ratio is presently 0.5 days.
Barinthus Biotherapeutics Stock Up 0.1%
BRNS stock opened at $0.56 on Friday. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $1.83. The firm’s 50-day simple moving average is $0.65 and its 200 day simple moving average is $0.65. The stock has a market cap of $22.79 million, a PE ratio of -0.43 and a beta of -0.41.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.14.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on BRNS
Hedge Funds Weigh In On Barinthus Biotherapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in BRNS. Baird Financial Group Inc. increased its position in Barinthus Biotherapeutics by 108.2% in the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares during the period. Renaissance Technologies LLC raised its stake in Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after acquiring an additional 76,800 shares in the last quarter. Finally, Rangeley Capital LLC raised its stake in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares in the last quarter. 25.20% of the stock is currently owned by institutional investors and hedge funds.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Featured Stories
- Five stocks we like better than Barinthus Biotherapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
